Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1213-1224

  Saxena, V ^a   Manos, M M ^b   Yee, H S ^a,c   Catalli, L ^a   Wayne, E ^a   Murphy, R C ^b   Shvachko, V A ^b   Pauly, M P ^b   Chua, J ^c   Monto, A ^a,c   Terrault, N A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; BOCEPREVIR; ELTROMBOPAG; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHILD PUGH SCORE; CLINICAL TRIAL; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 84899118885     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12718     Document Type: Article

References (37)

1. Edlin BR,. Hepatitis C screening: getting it right. Hepatology 2013; 57: 1644-50.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
3. Alter MJ, Hadler SC, Judson FN, et al,. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231-5.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
5. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
6. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
7. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
8. Product Information. Incivek [telaprevir]. Cambridge: MVPIM.
9. Product Information. Victrelis [boceprevir]. Whitehouse Stataion, NJ: Whitehouse Station NMC, Inc., May 2011.
10. Saxena V, Terrault N,. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012; 17: 216-24.
11. Gordon N,. Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2007 California Health Interview Survey. Internal Report: Kaiser Permanente Division of Research, 2012.
12. Krieger N,. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992; 82: 703-10.
13. Yee HS, Chang MF, Pocha C, et al,. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012; 107: 669-89.
14. Maasoumy B, Cobb B, Bremer B, et al,. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 2014; 39: 85-92.
15. Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T,. Hepatitis C genotype 6: a concise review and response-guided therapy proposal. World J Hepatol 2013; 5: 496-504.
16. Lawitz E, Poordad F, Brainard D, et al,. Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC LB4.
17. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23.
18. Curry M, Forns X, Chung R, et al,. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC; Abstract 213.
19. Jacobson I, Ghalib R, Rodriguez-Torres M, et al,. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC; Abstract LB3.
20. Zeuzem S, Dusheiko G, Salupere R,. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC; Abstract 1085.
21. Lawitz E, Ghalib R, Rodriguez-Torres M, et al,. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA; Abstract 155LB.
22. Iacobellis A, Siciliano M, Annicchiarico BE, et al,. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-53.
23. Carrion JA, Martinez-Bauer E, Crespo G, et al,. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28.
24. Reiberger T, Rutter K, Ferlitsch A, et al,. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011; 9: 602-8. e1.
25. Liu C, Zhu H, Tu Z, Xu YL, Nelson DR,. CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 2003; 37: 1335-42.
26. Fontaine H, Hezode C, Dorival C, et al,.; ANRS CO20 CUPIC study group. SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 221 cirrhotic non-responders treated in the French early access program (ANRS CO20-CUPIC). 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 60.
27. Bichoupan K, Schwartz JM, Martel-Laferriere V, et al,. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014; 39: 209-16.
28. Ogawa E, Furusyo N, Nakamuta M, et al,. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38: 1076-85.
29. Dienstag JL, McHutchison JG,. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
30. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al,. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
31. Schmid M, Kreil A, Jessner W, et al,. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005; 54: 1014-20.
32. Peck-Radosavljevic M,. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13: 317-23.
33. Larrey D, Lohse AW, de Ledinghen V, et al,. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57: 39-46.
34. Bruno S, Zuin M, Crosignani A, et al,. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104: 1147-58.
35. Rowe IA, Houlihan DD, Mutimer DJ,. Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Aliment Pharmacol Ther 2012; 36: 670-9.
36. Forns X, Garcia-Retortillo M, Serrano T, et al,. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
37. Everson GT, Terrault NA, Lok AS, et al,. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-62.